Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'.
Larissa Valor-Méndez,Koray Tascilar,David Simon,J. H. W. Distler,Arnd Kleyer,Georg Schett,Juergen Rech +6 more
TLDR
In this paper, the authors investigated the immune response to SARS-CoV-2 vaccination in patients with AIDs and found no improvement of COVID-19 on IL-1 blockade.Abstract:
We read with interest the work by Geisen and colleagues1 on the efficacy and safety of anti-SARS-CoV-2 mRNA vaccine in patients with rheumatic diseases. While substantial data on the efficacy and safety of SARS-CoV-2 vaccination have been created during the last months, it is currently unclear whether the vaccination is efficacious and safe in patients with autoinflammatory diseases (AIDs). These patients present with exacerbated innate immune responses associated with enhanced production of interleukin (IL)-1.2
Testing the immune response to SARS-CoV-2 vaccination in patients with AIDs is of interest, as IL-1 has been involved in the pathogenesis of COVID-19; thus, IL-1 expression is massively increased in patients with severe COVID-19.3–5 Furthermore, COVID-19 has shown to trigger an increased inflammatory disease activity in patients with AIDs.6 7 In addition, IL-1 inhibition has been applied in the treatment of COVID-19 and while initial uncontrolled studies revealed promising results,8 a randomised controlled trial showed no improvement of COVID-19 on IL-1 blockade.9 While current data suggest the immune response to SARS-CoV-2 vaccination may be reduced in certain diseases, such as rheumatoid arthritis,10 and certain treatments such as methotrexate,11 such data cannot be applied to AID or to IL-1 inhibitors as the underlying pathophysiology is fundamentally different. Hence, we aimed to investigate SARS-CoV-2 vaccination …read more
Citations
More filters
Journal ArticleDOI
Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis.
Anuraag Jena,Mark,Shubhra Mishra,Parakkal Deepak,Praveen Kumar-M,Aman Sharma,Y. Patel,Nicholas A. Kennedy,Alfred H.J. Kim,Vishal Sharma,Shaji Sebastian +10 more
TL;DR: In this paper, a systematic review about seroconversion after SARS-CoV-2 vaccination in patients with IMIDs and impact of various drugs on seroconversation rates was performed.
Journal ArticleDOI
Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis
TL;DR: In this paper , the authors performed a systematic review about seroconversion after SARS-CoV-2 vaccination in patients with IMIDs and the impact of various drugs on seroconversation rates.
Journal ArticleDOI
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review
Simon Galmiche,Liem Binh Luong Nguyen,Eric Tartour,Xavier de Lamballerie,Linda Wittkop,Paul Loubet,Odile Launay +6 more
TL;DR: In this paper, the authors conducted a systematic review of literature to assess immunogenicity, efficacy and effectiveness of COVID-19 vaccines in immunocompromised populations, including solid organ transplant recipients and patients with haematological malignancy.
Journal ArticleDOI
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review
TL;DR: In this article , the authors conducted a systematic review of literature to assess immunogenicity, efficacy and effectiveness of COVID-19 vaccines in immunocompromised populations, including solid organ transplant recipients and patients with haematological malignancy.
Journal ArticleDOI
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations
TL;DR: In this article , the COVID-19 pandemic has brought challenges for people with rheumatic disease in addition to those faced by the general population, including concerns about higher risks of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
References
More filters
Journal ArticleDOI
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
TL;DR: The epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of patients with laboratory-confirmed 2019-nCoV infection in Wuhan, China, were reported.
Journal ArticleDOI
Factors associated with COVID-19-related death using OpenSAFELY.
Elizabeth A. Williamson,Alex J Walker,Krishnan Bhaskaran,Seb Bacon,Chris Bates,Caroline E Morton,Helen J Curtis,Amir Mehrkar,David M. Evans,Peter Inglesby,Jonathan Cockburn,Helen Mcdonald,Brian MacKenna,Laurie A. Tomlinson,Ian J. Douglas,Christopher T Rentsch,Rohini Mathur,Angel Y S Wong,Richard Grieve,David G. Harrison,Harriet Forbes,Anna Schultze,Richard Croker,John Parry,Frank Hester,Sam Harper,Rafael Perera,Stephen J. W. Evans,Liam Smeeth,Ben Goldacre +29 more
TL;DR: A range of clinical factors associated with COVID-19-related death is quantified in one of the largest cohort studies on this topic so far and includes people of white ethnicity, Black and South Asian people were at higher risk, even after adjustment for other factors.
Journal ArticleDOI
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
TL;DR: Monotherapy blocking IL-1 activity in autoinflammatory syndromes results in a rapid and sustained reduction in disease severity, including reversal of inflammation-mediated loss of sight, hearing and organ function.
Journal ArticleDOI
COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
TL;DR: Whether such therapies may pose a risk — or even a benefit — in the context of the current COVID-19 pandemic is discussed.
Journal ArticleDOI
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.
Ulf Geisen,Dennis K Berner,Florian Tran,Melike Sümbül,Lena Vullriede,Maria Ciripoi,Hayley M Reid,Annika Schaffarzyk,Ann C Longardt,Jeanette Franzenburg,Paula Hoff,Jan H. Schirmer,R Zeuner,Anette Friedrichs,Andrea Steinbach,Christine Knies,Robert Markewitz,Peter J Morrison,Sascha Gerdes,Stefan Schreiber,Bimba F. Hoyer +20 more
TL;DR: In this paper, the efficacy and safety of anti-SARS-CoV-2 mRNA vaccines in a cohort of immunosuppressed patients as compared with healthy controls were presented for the first time.